2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Ovarian Neoplasms
3
Lymphoma, Non-Hodgkin
3
Lymphoma, T-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lung Neoplasms
2
Hodgkin Disease
2
Glioma
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Mantle-Cell
1
Interventions
Temozolomide
15
Radiotherapy
11
Everolimus
6
Bevacizumab
6
Irinotecan
5
Cyclophosphamide
5
ribociclib
4
Radiation
4
Panobinostat
4
TIC10 compound
3
Specimen Handling
3
Re-Irradiation
3
Etoposide
3
Dasatinib
3
pembrolizumab
2
nimotuzumab
2
abemaciclib
2
Vorinostat
2
Valproic Acid
2
Topotecan
2
Nivolumab
2
Mebendazole
2
Magnetic Resonance Spectroscopy
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Gemcitabine
2
GDC-0084
2
Erlotinib Hydrochloride
2
Diphtheria-Tetanus Vaccine
2
Cilengitide
2
Cetuximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Diffuse Intrinsic Pontine Glioma
×
Pharmacogenomic Variants
×
Clear all
NCT01165333
2026-03-16
CILENT
Centre Oscar Lambret
Phase 1
Completed
32 enrolled